Literature DB >> 16511922

Polymorphism of the FcgammaRIIalpha IgG receptor in patients with lupus nephritis and glomerulopathy.

Adriana Peixoto Gelmetti1, Antônio Carlos Freitas, Viktoria Woronik, Rui Toledo Barros, Eloísa Bonfá, Renato Costa Monteiro.   

Abstract

OBJECTIVE: FcgammaRIIalpha is a low affinity receptor that has 2 codominantly expressed alleles, R131 and H131, which differ in their ability to bind immunoglobulin G (IgG) subclasses. Cells expressing H131 bind more efficiently complexed IgG2 than those expressing the R131 variant. The FcgammaRIIalpha polymorphism has been shown to be associated with lupus nephritis. We evaluated the relevance of FcgammaRIIalpha gene polymorphism in the development of lupus immune complex mediated nephritis, as well as its clinical and histological characteristics, by comparing the genotype and allelic distribution of this receptor in lupus nephritis to ethnically matched Brazilian patients with primary glomerulonephritis.
METHODS: Patients with lupus nephritis (n = 76) and patients with diagnosis of primary glomerulonephritis (n = 63) established by kidney biopsies were recruited. FcgammaRIIalpha genotyping was performed by polymerase chain reaction with allele-specific primers to distinguish between the 2 allelic forms (H131 and R131).
RESULTS: We observed a skewed frequency of genotype FcgammaRIIalpha-R/R131 and the R131 allele in patients with lupus nephritis compared to primary glomerulopathies (p < 0.05), which disappeared when we compared this population with lupus nephritis only to the group with proliferative glomerulonephritis (IgA nephropathy, membranoproliferative glomerulonephritis, and mesangial proliferative glomerulonephritis). No association was found between genotype distribution and histological class of lupus nephritis or renal insufficiency available at the beginning and end of followup. We found an association of genotype FcgammaRIIalpha-R/R131 with higher antinuclear antigen titers and complement 3 consumption (p < 0.05).
CONCLUSION: The skewed distribution of FcgammaRIIalpha genotypes with the predominance of homozygous R/R131 genotype observed in patients with lupus nephritis over nonproliferative idiopathic glomerulonephritis emphasizes its importance as a heritable risk factor for immune complex mediated renal injury in Brazilian patients with lupus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16511922

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

Review 1.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

Review 2.  Functional and clinical consequences of Fc receptor polymorphic and copy number variants.

Authors:  S Bournazos; J M Woof; S P Hart; I Dransfield
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 3.  The contribution of the programmed cell death machinery in innate immune cells to lupus nephritis.

Authors:  FuNien Tsai; Harris Perlman; Carla M Cuda
Journal:  Clin Immunol       Date:  2016-10-22       Impact factor: 3.969

Review 4.  Genetics of human lupus nephritis.

Authors:  Taro Iwamoto; Timothy B Niewold
Journal:  Clin Immunol       Date:  2016-09-28       Impact factor: 3.969

Review 5.  Genetics of Lupus Nephritis: Clinical Implications.

Authors:  Melissa E Munroe; Judith A James
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

6.  Meta analysis on the association between FcgammaRIIa-R/H131 polymorphisms and systemic lupus erythematosus.

Authors:  Hui Yuan; Hai-Feng Pan; Lian-Hong Li; Jin-Bao Feng; Wen-Xian Li; Xiang-Pei Li; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2008-06-06       Impact factor: 2.316

7.  FcγRIIa defunctioning polymorphism in paediatric patients with renal allograft.

Authors:  Fatina I Fadel; Manal F Elshamaa; Ahmed Salah; Eman A Elghoroury; Safaa Abd El-Rahman; Mona Hamed Ibrahim; Solaf Kamel
Journal:  Cent Eur J Immunol       Date:  2017-12-30       Impact factor: 2.085

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.